In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.
about
Treatment and prophylaxis of invasive candidiasisStructure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic PropertiesPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel EchinocandinAnidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trialSafety and pharmacokinetics of multiple-dose anidulafungin in infants and neonatesTreatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.Micafungin in the treatment of candiduria: A case series.Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasisTissue penetration of antifungal agents.Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.Antifungal prophylaxis with anidulafungin to minimize drug interactions with an antiepileptic treatment in a hematopoietic stem cell transplant recipient.Anidulafungin and its role in candida infectionsResource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.Scedosporium apiospermum infection of the urinary system with a review of treatment options and cases in the literature.Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.Tissue distribution of anidulafungin in neonatal rats.Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges.Anidulafungin--challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies.Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
P2860
Q27001567-D328A323-A4F8-4A33-BF05-E3076DC51B32Q28817906-0C2D7CDF-D9D8-4A80-9197-53B031C547CCQ28821330-F78389AB-87F8-4700-904D-E9B50B72729FQ33490772-35A8C843-DEDA-468B-A8F8-1A3019241FEAQ34724039-37A92F79-DCD7-4A45-A926-00D4F1828EFBQ35071572-AC97BC3D-A6C1-4481-B982-F2D250324CB7Q35959489-1D59827E-5C44-46BF-89D7-DE880004F4D9Q36434403-5707AC0E-0EC7-4B0C-8DAF-65A33C0A73F9Q36577831-FA0AD933-C023-47E2-A0C9-1EEA16FB28FFQ36757660-B498DC7E-CAAC-4724-A843-AC0A11ECD293Q37544911-7082FC96-C61E-444D-88DD-B7C445D70F3BQ37720796-6A53AC84-10D7-4628-8FF2-503F8CD3D9EAQ37785979-DC4A5763-533B-4A75-8AC1-042F675FED46Q37854724-A1358B75-93AC-4E2B-9CF6-24184C41A428Q37904672-7FBBF42E-161D-457E-9715-7A2E6BB0D1B1Q38681635-E7962386-C030-4B53-BFA2-1546854CAF48Q38684505-908DC0DD-56BE-4374-842E-34E247E07CBDQ41031277-D6FF7CF0-BC09-4222-AC82-390F7B14008AQ41161488-BAD6CD8B-95FC-470A-B20C-01EDAC7056B0Q42731827-354D4C9D-2C9F-4C06-90F1-382407DDC1CDQ45892642-548EC20B-4796-4A9B-B800-F74F03245BE6Q46266934-C8315648-C428-4370-8B31-6640DBC23E53Q48192025-9BEFDD87-E9FA-4CC5-BDCE-2448E6127857Q48670237-F26C3DF6-9DE8-405C-A15A-ED2CD329E36CQ50536031-7590043E-CCB8-468C-A9B4-E39725C5C685Q51339243-FE46654D-8B61-4CB0-B541-661A9344202BQ57746174-B0A717EB-C3B4-4082-9986-6C0126511443
P2860
In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
In vitro and in vivo studies t ...... interactions of anidulafungin.
@en
In vitro and in vivo studies t ...... interactions of anidulafungin.
@nl
type
label
In vitro and in vivo studies t ...... interactions of anidulafungin.
@en
In vitro and in vivo studies t ...... interactions of anidulafungin.
@nl
prefLabel
In vitro and in vivo studies t ...... interactions of anidulafungin.
@en
In vitro and in vivo studies t ...... interactions of anidulafungin.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo studies t ...... interactions of anidulafungin.
@en
P2093
Bharat D Damle
Gregory L Weber
James A Dowell
Martin Stogniew
Philip B Inskeep
Robert L Walsky
P2860
P304
P356
10.1128/AAC.01279-08
P407
P577
2008-11-24T00:00:00Z